DTB commentary: Effect of dapagliflozin on cardiovascular events in patients with type 2 diabetes

Expert commentary is provided for large RCT (n=17,160) which found dapagliflozin was non-inferior to placebo for major adverse cardiac events in type 2 diabetes patients; but decreased death or hospitalisation for heart failure and reduced adverse renal events.

Drug and Therapeutics Bulletin